Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in... see more

TSXV:BTI.H - Post Discussion

View:
Post by LOOPA441 on Apr 10, 2022 7:18pm

XB3-001

XB3-001:

If money has been the reason this program has stalled, why hasn't the company leveraged its contacts to find capital from friendly entities?

Our board member, David Wirzer, is EVP and CIO at conneticut innovations (CI). Surely a man of his stature could help raise enough non-dilutive capital for a Phase 1 trial ($10,000,000?) to move things forward, especially considering the technology has never failed.

Either the sources of capital don't like what we have (Why?), or we're not active enough.

Let's make it happen.


https://www.bioasis.us/about/board-of-directors/david-m-wurzer/
https://ctinnovations.com/obtain-funding/venture-solutions/connecticut-bioscience-innovation-fund/

"Connecticut Innovations will make investments from the $200 million CBIF over the next 10 years in the form of grants, equity investments and loans to speed commercializable bioscience breakthroughs to market. Startups and early-stage businesses may apply for secured convertible loans or equity. "
Comment by JDavenport on Apr 10, 2022 11:57pm
About xB3-001, jaysus, you're all over the place. xB3-001 is preclinical and not yet commercializable. I would think it's way short of qualifying at David Wurzer's Connecticut Innovations. It wouldn't surprise me if xB3-001 is being worked on at Daiichi Sankyo, Protalix or somewhere else for reasons I have posted several times. jd
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities